![]() |
市場調查報告書
商品編碼
1949518
質譜儀市場 - 全球產業規模、佔有率、趨勢、機會及預測(依產品、技術、應用、地區及競爭格局分類),2021-2031年Mass Spectrometry Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Technology, By Application, By Region & Competition, 2021-2031F |
||||||
全球質譜儀市場預計將從 2025 年的 54.3 億美元成長到 2031 年的 82.2 億美元,複合年成長率達到 7.15%。
質譜分析是一種用於測量離子質荷比的分析技術,能夠對複雜樣品中的化學物質進行精確的鑑定和定量。全球質譜市場的主要驅動力是蓬勃發展的製藥業,該行業對藥物研發和生物製藥的投資不斷增加,需要進行深入的分子分析。此外,政府對食品安全和環境保護的嚴格監管要求該行業使用高靈敏度的檢測設備以確保合規,從而導致對先進計量設備的需求不斷成長。
| 市場概覽 | |
|---|---|
| 預測期 | 2027-2031 |
| 市場規模:2025年 | 54.3億美元 |
| 市場規模:2031年 | 82.2億美元 |
| 複合年成長率:2026-2031年 | 7.15% |
| 成長最快的細分市場 | 蛋白質體學 |
| 最大的市場 | 北美洲 |
然而,這些系統所需的大量資本投入構成了市場推廣的一大障礙,尤其對於資金有限的學術機構和小規模實驗室而言更是如此。德國產業協會SPECTARIS預測,到2024年,分析、生物和實驗室技術領域將經歷一個整合階段,並實現中等個位數的收入成長。這項資訊表明,儘管高成本仍然是一個重大障礙,但由於這些儀器在工業和科研領域不可或缺,市場成長將得以持續。
質譜技術在藥物研發和臨床診斷中的日益普及是推動市場發展的主要動力。隨著對更嚴格的處方和精準醫療的需求不斷成長,實驗室擴大採用這些先進系統來處理治療監測和生物標記檢驗。該技術提供的精準分子分析能力對於滿足不斷變化的醫療法規至關重要。例如,島津公司在其2025年8月發布的「截至2025年6月的會計年度第一季合併合併會計」中報告稱,其分析測量儀器事業部銷售額達757.89億日元(較上年同期成長2.7%)。這主要得益於臨床和藥物檢測領域質譜儀系統銷售的成長。
此外,混合和高解析度系統的技術進步正成為關鍵驅動力,使製造商能夠透過提升儀器性能來開拓新的收入來源。速度和靈敏度的提升正在推動工業和研究領域的設施現代化,並在普遍的經濟挑戰下支撐成長。這一趨勢體現在近期發布的財務業績中,例如布魯克公司於2025年5月發布的「2025年第一季」報告顯示,其營收達到8.014億美元(年增11.0%),這主要得益於其先進的技術組合,包括質譜技術。此外,沃特世公司於2025年2月發布的「2024年度報告」也顯示了成熟市場的龐大規模,預測其2025會計年度淨銷售額將達到29.58億美元,凸顯了市場對分析儀器的持續需求。
質譜系統建設所需的大量初始投資是其廣泛應用的主要障礙,尤其對於預算有限的學術機構和小規模實驗室而言更是如此。這些複雜的分析儀器由於其高度技術化的設計而高成本,而基礎設施升級、專業人員培訓和日常維護的成本進一步增加了總擁有成本。因此,當機構面臨財務困境時,這些昂貴設備的購買往往會被推遲或取消,直接阻礙了市場擴張。
這種對實施成本的脆弱性也反映在近期貿易統計數據中,採購活動有所下降。德國產業協會SPECTARIS報告稱,2024年分析、生物和實驗室技術領域的國際銷售額較去年同期下降6.8%。這項降幅凸顯了高昂的資本需求以及經濟壓力如何限制了終端用戶投資新技術的能力。因此,市場正經歷一段需求低迷期,購買這些關鍵工具的財務負擔超過了潛在買家的直接營運需求。
攜帶式和小型化質譜儀的出現,使得在需要時即可進行高精度化學分析,從而促進了產業的去中心化。這項創新滿足了法醫安全、國防和生物加工等領域對快速決策的迫切需求,在這些領域,將樣品運送到中心實驗室在物流方面極具挑戰性。市場對能夠在非標準環境下提供檢體級精度的攜帶式儀器的強勁需求,推動了現場應用型設備的普及。例如,908 Devices公司在2024年11月發布的「2024年第三季財報」中宣布,其營收年增17%。這一成長主要得益於該公司攜帶式質譜儀在國內外市場的快速部署。
同時,隨著各組織尋求將分析測試與企業淨零排放目標相契合,永續和環保質譜技術的進步正成為關鍵趨勢。製造商正在設計能夠降低能耗和溶劑消耗的系統,以減少質譜分析對環境的整體影響。這種營運模式的轉變正在影響籌資策略,促使企業優先選擇那些能夠證明檢驗永續性成果的供應商。根據安捷倫科技公司於2024年6月發布的《2024年ESG報告》,該公司40%的儀器總收入將來自獲得「My Green Lab ACT」認證標籤的儀器,這凸顯了企業對獲得環境認證技術的商業性偏好。
The Global Mass Spectrometry Market is projected to expand from USD 5.43 Billion in 2025 to USD 8.22 Billion by 2031, achieving a compound annual growth rate (CAGR) of 7.15%. Mass spectrometry is an analytical method designed to measure the mass-to-charge ratio of ions, facilitating the exact identification and quantification of chemical substances within intricate samples. This global sector is largely underpinned by the flourishing pharmaceutical industry, where rising investments in drug discovery and biologics necessitate thorough molecular analysis. Furthermore, rigorous government mandates regarding food safety and environmental preservation require industries to utilize highly sensitive testing apparatus to guarantee compliance, consequently boosting the demand for sophisticated instrumentation.
| Market Overview | |
|---|---|
| Forecast Period | 2027-2031 |
| Market Size 2025 | USD 5.43 Billion |
| Market Size 2031 | USD 8.22 Billion |
| CAGR 2026-2031 | 7.15% |
| Fastest Growing Segment | Proteomics |
| Largest Market | North America |
Nevertheless, the substantial capital expenditure needed for these systems stands as a major obstacle to wider market uptake, especially for academic institutions and smaller laboratories with constrained funds. In 2024, the German Industry Association SPECTARIS anticipated that the analytical, bio, and laboratory technology sector would realize revenue growth in the mid-single-digit percentages following a consolidation phase. This information highlights that, although elevated costs pose a significant barrier, the indispensable nature of these instruments for industrial and research purposes ensures that market growth is maintained.
Market Driver
The escalating integration of mass spectrometry within pharmaceutical research and clinical diagnostics acts as a principal catalyst for market development. As the requirements for rigorous drug formulation and precision medicine grow, laboratories are progressively adopting these sophisticated systems to handle therapeutic monitoring and biomarker validation. The capacity of this technology to deliver exact molecular analysis is proving essential for meeting changing healthcare regulations. For example, Shimadzu Corporation reported in its 'Consolidated Financial Results for the Three Months Ended June 30, 2025', released in August 2025, that its Analytical & Measuring Instruments segment achieved net sales of 75,789 million yen, a 2.7% year-on-year rise attributed to stronger sales of mass spectrometer systems in clinical and pharmaceutical testing sectors.
Additionally, technological progress in hybrid and high-resolution systems functions as a crucial driver, allowing manufacturers to secure new income sources through improved instrument performance. Improvements in speed and sensitivity are prompting facility modernizations across industrial and research landscapes, thereby supporting growth despite wider economic difficulties. This pattern is reflected in recent financial results; for instance, Bruker Corporation's 'First Quarter 2025 Financial Results' from May 2025 indicated revenues of $801.4 million, an 11.0% increase led by its advanced technology portfolio, including mass spectrometry. Moreover, demonstrating the substantial magnitude of the established market, Waters Corporation's '2024 Annual Report' from February 2025 revealed total net sales of $2.958 billion for the fiscal year, highlighting the persistent demand for analytical equipment.
Market Challenge
The substantial capital outlay necessary for mass spectrometry systems presents a significant hurdle to widespread adoption, especially for academic institutions and smaller laboratories managing limited budgets. These complex analytical instruments incur premium costs due to their sophisticated engineering, while the total cost of ownership is further inflated by expenditures for infrastructure upgrades, specialized staff training, and routine maintenance. Consequently, when organizations encounter financial restrictions, the acquisition of such expensive assets is frequently postponed or canceled, which directly impedes market volume growth.
This vulnerability to acquisition costs is evident in recent trade figures showing a reduction in procurement activities. In 2024, the German Industry Association SPECTARIS reported that the analytical, bio, and laboratory technology sector experienced a 6.8 percent decline in international sales relative to the prior year. This decrease highlights how substantial capital demands, coupled with economic strains, restrict the capacity of end-users to invest in new technologies. Consequently, the market undergoes phases of suppressed demand wherein the financial strain of obtaining these critical tools exceeds the immediate operational requirements of prospective buyers.
Market Trends
The emergence of handheld and miniature mass spectrometers is progressively decentralizing the industry by facilitating high-fidelity chemical analysis directly at the point of need. This innovation meets the urgent demand for rapid decision-making in fields like forensic safety, defense, and bioprocessing, where transporting samples to central labs is logistically impractical. The transition toward field-ready units is supported by robust demand for portable devices that provide laboratory-grade results in non-standard settings. For example, 908 Devices announced in its 'Third Quarter 2024 Financial Results' in November 2024 that it achieved a 17% year-over-year revenue increase, a growth figure driven primarily by the rapid deployment of its handheld mass spectrometry tools across domestic and international markets.
Concurrently, the advancement of sustainable and eco-friendly mass spectrometry technologies has emerged as a crucial trend as organizations aim to align analytical testing with corporate net-zero goals. Manufacturers are designing systems that reduce energy usage and solvent consumption to decrease the overall environmental impact of mass analysis. This operational shift is influencing procurement strategies to prefer vendors that show verifiable sustainability achievements. According to the '2024 ESG Report' by Agilent Technologies released in June 2024, instruments bearing the My Green Lab ACT-certification label now comprise 40% of the company's total instrument revenue, underscoring the commercial preference for environmentally certified technologies.
Report Scope
In this report, the Global Mass Spectrometry Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Mass Spectrometry Market.
Global Mass Spectrometry Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: